Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Brain Metastases|HR+ Metastatic Breast Cancer
Interventions: RADIATION: Stereotactic Radiosurgery (SRS)|DRUG: Abemaciclib|DRUG: Endocrine therapy
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Eli Lilly and Company